

FOR IMMEDIATE RELEASE

COMPANY CONTACT:

James R. Miller, Pinnacle
President & CEO
1 (240) 372-4599

PINNACLE BIOLOGICS ANNOUNCES CONTRACT WITH CHILTERN

ROCKVILLE, Md. – June 23, 2008 – Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an agreement with Chiltern International, Inc. for the activities of pharmacovigilance/safety reporting and medical information services for Western Europe.

James R. Miller, President & CEO of Pinnacle Biologics stated, “The completion of the Chiltern agreement represents a significant step in the process of offering a full range of services and solutions to the pharmaceutical/biotechnology companies that we currently represent or will partner with in the future. We are proud to be associated with Chiltern.”

“Chiltern is extremely excited about expanding our service portfolio to meet the Pinnacle Biologics unique Pharmacovigilance, Safety and Medical Information requirements and help accelerate the commercialization of pharmaceutical products that are promoted and distributed by Pinnacle.” noted Glenn Kerkhof, Chief Executive Officer of Chiltern

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilance, product safety, market research and administrative services.

Pinnacle holds executive offices in Bannockburn, Illinois, satellite offices in Rockville, Maryland, and Almere, The Netherlands. Further information is available at www.pinnaclebiologics.com

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern employs more than 1,200 people with 23 offices across the United States, Europe, Latin America and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Further information is available at www.chiltern.com